NASDAQ:ICCC
Immucell Corp.
Immucell Corp.'s revenue grew 4.3% in fiscal 2025 to $27.6M while operating margin rose to 6.0%, its highest in 9 years. Free cash flow was $1.2M, 4.4% of revenue, and the diluted share count rose 10.5%.Summary generated from Immucell Corp.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$27.6M
Revenue growth+4.3%
Revenue, 5-yr CAGR+12.5%
Gross margin41.4%
Operating margin6.0%
Net margin−3.8%
ROIC3.9%
Return on equity−3.8%
Debt / equity0.34
Free cash flow$1.2M
FCF margin4.4%
Share count change+10.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 19 | 19 | 17 | 26 | 28 |
| Operating income | 0 | −2 | −6 | −2 | 2 |
| Net income | −0 | −2 | −6 | −2 | −1 |
| Free cash flow | −2 | −6 | −7 | −0 | 1 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KResults of operations and financial condition
Jul 9, 2026 - 4Insider transaction report
Jun 22, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 8-KRegulation FD disclosure
Jun 10, 2026 - 8-KResults of operations and financial condition
May 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026